COVID-19: Pharmidex Contingency Plan
Mar 19, 2020

Pharmidex are taking all the necessary steps to ensure the progression of client studies during these difficult time.

COVID-19: Pharmidex Contingency Plan


We are taking all necessary steps to ensure that studies proceed, while preserving the health and safety of staff. Summary of key steps taken at Pharmidex:


- Following the relevant guidelines issued by Public Health England.


- Limiting access to only essential people in our laboratories and cancelling/rescheduling all non-critical visitors. All visitors must confirm COVID-19 status prior to arrival.


- Cancelled all non-essential business travel.


- Closely communicating with suppliers regarding the status of their inventories and their business continuity plans and identifying alternate sources for supplies.


- Implemented strict sanitization practices to prevent cross contamination between staff, including providing our staff with resources and up-to-date information and guidance.


- To prevent the potential spread of the infection amongst employees, staff will declare any potential close contact with infected individuals and follow the relevant health guidelines.


- Our operations team will ensure adequate staffing cover so as not to compromise client studies.


We will keep you updated if the situation changes resulting in any impact on progression of your projects.


Best wishes to everyone during these tough times.

24 Apr, 2024
Pharmidex , in collaboration with colleagues at the University of Brighton, is pleased to announce publication of our latest article
13 Mar, 2024
Uncover valuable insights from a range of sources including plasma, bronchoalveolar lavage fluid, urine, and tissue supernatant with our comprehensive matrix evaluation services.
By Ash Alavijeh 26 Feb, 2024
As an accredited GLP/GCP laboratory, Pharmidex provides comprehensive bioanalytical solutions tailored to meet your specific drug development needs.
More Posts
Share by: